Inactivated combined Newcastle disease virus La Sota and avian influenza subtype H9 Strain F antigen concentrate is processed into water-in-oil emulsions for subcutaneous or intramuscular injection in commercial layer and breeder flocks. The aqueous antigen phase is thawed and held at 2–8°C. It is adjusted to pH 7.2–7.4 with sterile buffer before the oil phase is introduced. The oil phase is prepared from light mineral oil and a mannide oleate surfactant. It is warmed to 31–35°C to reduce viscosity before mixing. The phases are combined in an inline rotor-stator mixer configured for water-in-oil emulsion formation. The finished dose volume is normally 0.5 mL per bird by subcutaneous or intramuscular injection, although the registered dose controls final administration. Antigen inclusion is based on pre-inactivation hemagglutination titre measured by hemagglutination and hemagglutination-inhibition methods given in WOAH Terrestrial Manual Chapter 3.3.4 and Chapter 3.3.14. Emulsion checks include visual phase separation, droplet size distribution by laser diffraction according to ISO 13320-1:2020, and dynamic viscosity by rotational viscometer according to ISO 2555. In layer and breeder programs, the emulsified vaccine is used to induce active immunity against Newcastle disease virus and H9 low-pathogenic avian influenza and to support maternal antibody transfer through yolk. This application is particularly relevant where field exposure to H9 subtype virus is continuous and where live virus cannot be introduced into multi-age layer complexes. Vaccines are pre-warmed to 20–25°C before injection to reduce tissue reaction and to stabilise syringe flow. Potency is confirmed by vaccination-challenge or serological correlation according to WOAH Chapter 3.3.4 and Chapter 3.3.14.

How Does Residual Inactivation Chemistry Constrain Final Emulsion Stability?

The antigen concentrate may carry residual formaldehyde or beta-propiolactone depending on the inactivation route. Free formaldehyde is measured by Ph. Eur. 2.4.18 or a validated equivalent colorimetric method. If the value exceeds the registration-directed limit, the aqueous phase is neutralized with sodium metabisulfite at a molar ratio not greater than 1.2:1 relative to free formaldehyde. The neutralization reaction lowers pH. The aqueous phase is therefore restored to pH 7.2–7.4 before emulsification because acidic conditions accelerate antigen aggregation. When beta-propiolactone is used, residual alkylating activity is quenched by sodium thiosulfate at 1.0–1.2 molar equivalent after full inactivation. The residual chemistry must be controlled before oil-phase addition because polar inactivation by-products partition at the oil-water interface. Uncontrolled residual formaldehyde can destabilize the interfacial film and produce a bimodal droplet distribution. Antigen release from the internal aqueous phase then becomes erratic. Batch records therefore include a pre-emulsification check for residual formaldehyde, pH, and water-phase turbidity before the rotor-stator unit is started. The holding time between neutralization and emulsification is maintained at 2–8°C and normally does not exceed 8 h to limit re-aggregation. Any deviation in pH outside 7.2–7.4 at the point of oil addition is recorded and the bulk is re-adjusted before release to emulsification.

Regional H9 field drift changes the antigenic distance between the H9 Strain F component and circulating isolates in breeder and layer regions. Hemagglutination-inhibition cross-reactivity is measured against the field isolate using the antigen standards in WOAH Terrestrial Manual Chapter 3.3.4. The HI titre is recorded as log2 reciprocal endpoint. A difference of 1–2 log2 between the vaccine strain F and a circulating isolate is often used as a review trigger. Final strain replacement, however, follows national efficacy data and field challenge proof. For autogenous registration, the inactivated antigen concentrate can be blended directly into a region-specific emulsion after the HA gene sequence and HI profile are reviewed. The same oil-emulsion platform is normally retained, but the H9 antigen fraction is replaced or supplemented. Published data for the exact antigenic distance threshold for this specific Strain F configuration are limited. Each batch or regional autogenous product therefore is matched through HI cross-reactivity and fixed challenge studies. The La Sota component remains constant when Newcastle disease field challenge is stable. If a genotype VII Newcastle disease isolate becomes dominant, a separate strain revision may be required under the same national registration framework.

Oil-Phase Dispersal and Viscosity Control in Mineral Oil Systems

Mineral oil adjuvanted emulsions are manufactured at a typical oil-to-aqueous phase ratio of 70:30 w/w. Finished emulsion dynamic viscosity is measured by rotational viscometer according to ISO 2555. The injectable range is commonly 20–80 mPa·s at 25°C. Droplet size distribution is measured by laser diffraction according to ISO 13320-1:2020. The median droplet diameter is controlled to 0.5–2.0 μm. Larger droplets accelerate creaming and can delay antigen release from the internal aqueous phase. A bimodal distribution with a secondary peak above 5.0 μm indicates phase inversion or surfactant depletion. The aqueous antigen phase must be maintained at 20–25°C during high-shear mixing. Temperature excursion above 37°C denatures hemagglutinin and reduces vaccine potency. Jacketed mixing vessels and inline heat exchangers are used at production scale to remove shear-generated heat. The rotor-stator tip speed is adjusted so that the target droplet size is achieved in one pass. Recirculation flow is controlled to avoid air entrainment. Viscosity is checked after 24 h of quiescent storage because the emulsion undergoes initial structuring. If dynamic viscosity rises above 80 mPa·s after 24 h, the batch is re-homogenized under reduced shear or rejected based on injectability. The final container must pass syringeability testing through 21–23 G needles under registered vaccination conditions.

In polyvalent inactivated lines, the NDV La Sota and H9 Strain F concentrate is blended with inactivated infectious bronchitis virus, infectious bursal disease virus, egg drop syndrome virus, or reovirus antigens before oil emulsification. The blending sequence matters at production scale. The highest-viscosity antigen concentrate is added first to the aqueous phase, then the lower-viscosity fractions are introduced with gentle agitation. This order prevents local concentration gradients and reduces flocculation before the oil phase is added. Each component is standardized by its own potency test or antigen mass assay. The combined bulk is tested for sterility according to Ph. Eur. 2.6.1 and for general safety according to 9 CFR 113.33 or the applicable regional safety standard. Host-animal safety is confirmed by the final vaccine target species test under the relevant marketing authorisation. Antigen interference is assessed by comparing hemagglutination-inhibition titers after monovalent and polyvalent administration. No universal interference prediction is available. Batch-specific stability and potency data are required for each combination. The final emulsion should not be mixed with live vaccine diluents in the same syringe unless a compatibility study has been conducted. Oil-emulsion vehicles can inactivate live attenuated vaccine viruses on contact.

When Aseptic Filling Must Follow Inactivation Verification

After inactivation, the combined antigen bulk is held in quarantine until inactivation is confirmed. Inactivation verification is performed by passage in specific-pathogen-free embryonated chicken eggs according to WOAH Terrestrial Manual Chapter 3.3.4 and Chapter 3.3.14. Sterility of the inactivated aqueous bulk is tested by membrane filtration or direct inoculation according to Ph. Eur. 2.6.1. Free formaldehyde or residual alkylating agent is tested before filling because the filled container must retain the finished formulation. Filling lines for oil-emulsion vaccines use aseptic peristaltic pumps and single-use tubing. The fill room is maintained at 15–25°C. The bulk is continuously agitated at low speed to avoid phase separation. Fill volume checks are performed by gravimetric method at registered intervals. The closure system is chosen to withstand oil contact and to prevent leakage during cold-chain storage. Container closure integrity is tested by dye ingress or vacuum decay according to USP <1207> or an equivalent method. Any filling delay that exceeds the validated bulk holding time requires re-verification of pH, viscosity, and droplet size before filling resumes.

Finished emulsion batches are stored at 2–8°C with continuous temperature logging. Freeze-thaw cycling is not permitted because the oil film around internal water droplets ruptures and antigen release is altered. Accelerated storage at 25°C may be used for registration screening. It does not replace real-time stability data at 2–8°C. The registered shelf life for oil-emulsion inactivated poultry vaccines is commonly 18–24 months. The exact shelf life is established by real-time stability studies. Before batch release, droplet size, viscosity, sterility, safety, and potency are verified. Bacterial endotoxin is tested according to Ph. Eur. 2.6.14 where the marketing authorisation includes a limit. The aqueous inactivated antigen concentrate is not suitable for tablet, capsule, powder, granule or premix dosage formats because the protein-lipid viral particles aggregate under tableting pressure and destabilize during thermal drying; the only validated finished-dosage format is liquid injection or emulsion. The following table lists core batch-release controls applied to the combined NDV La Sota and H9 Strain F oil-emulsion vaccine.

Sizing Aqueous Antigen Concentrates Prior to High-Shear Emulsification

Clarification of the inactivated antigen concentrate before oil emulsification removes cell debris and reduces fouling in the rotor-stator unit. Depth filtration is used with a pressure differential that should not exceed 0.8 bar. Excessive pressure compacts the filter cake and lowers flux. The filtrate is checked for antigen recovery by hemagglutination assay before entering the aqueous phase tank. Any loss greater than 0.5 log2 HI units after clarification triggers a deviation review because the final antigen load shifts downward. The clarified aqueous phase is held at 2–8°C under continuous agitation before emulsification. Droplet sizing of the finished emulsion is the relevant control. Temperature of the clarified phase is raised to 20–25°C only immediately before emulsification to reduce thermal stress on the hemagglutinin. This step also prevents condensation when the cold aqueous phase meets the warm oil phase. The in-process hold time of the warmed aqueous phase before the shear step is limited to 4 h. After 4 h, the phase is returned to 2–8°C and sampled for pH and hemagglutination titre before mixing.